The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort

Foluso O. Ademuyiwa, Austin Miller, Tracey O'Connor, Stephen B. Edge, Mangesh A. Thorat, George W. Sledge, Ellis Levine, Sunil Badve

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

The use of clinicopathologic features in decision-making in early stage estrogen receptor (ER)-positive breast cancer (BC) may lead to over or under treatment. We investigated the effect of the Oncotype Dx® (ODX) on chemotherapy (CTX) utilization in two cancer centers. 276 cases of node-negative ER-positive BC had ODX between 2005 and 2009. Age at diagnosis, tumor size, grade, and progesterone receptor (PR) status were abstracted from records and provided to two medical oncologists blinded to the ODX score. A recommendation for or against CTX was made based on clinicopathologic characteristics. Median age was 55 years. Mean tumor size was 1.6 cm. The median 10-year Adjuvant! Online (AO) mortality risk was 8. The median Nottingham Prognostic Index (NPI) was 3.3. The median ODX recurrence score was 17. Without knowledge of the ODX, oncologists were more likely to recommend CTX to younger women (P < 0.0001), women with negative PR status (P < 0.0001), higher NPI (P < 0.012), and tumors > 1 cm (P = 0.033). On average, CTX recommended patients had larger tumors (2.0 vs. 1.2 cm) and higher AO 10-year mortality (11.4 vs. 4.4%). ODX resulted in a change in management for 38% of women. Of 188 total patients who did not receive CTX, 71 had a recommendation favoring CTX by an oncologist blinded to the ODX score. In our multi-institutional cohort, the ODX score had a significant impact on the receipt of adjuvant CTX and altered management for 38% of women.

Original languageEnglish
Pages (from-to)797-802
Number of pages6
JournalBreast Cancer Research and Treatment
Volume126
Issue number3
DOIs
StatePublished - Apr 2011

Fingerprint

Breast Neoplasms
Recurrence
Drug Therapy
Estrogen Receptors
Neoplasms
Mortality
Progesterone Receptors
Decision Making
Oncologists
Therapeutics

Keywords

  • Adjuvant chemotherapy
  • Breast cancer
  • Oncotype DX

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. / Ademuyiwa, Foluso O.; Miller, Austin; O'Connor, Tracey; Edge, Stephen B.; Thorat, Mangesh A.; Sledge, George W.; Levine, Ellis; Badve, Sunil.

In: Breast Cancer Research and Treatment, Vol. 126, No. 3, 04.2011, p. 797-802.

Research output: Contribution to journalArticle

Ademuyiwa, Foluso O. ; Miller, Austin ; O'Connor, Tracey ; Edge, Stephen B. ; Thorat, Mangesh A. ; Sledge, George W. ; Levine, Ellis ; Badve, Sunil. / The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. In: Breast Cancer Research and Treatment. 2011 ; Vol. 126, No. 3. pp. 797-802.
@article{307614b438ad4f2c9d65c850c3c4bcb6,
title = "The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort",
abstract = "The use of clinicopathologic features in decision-making in early stage estrogen receptor (ER)-positive breast cancer (BC) may lead to over or under treatment. We investigated the effect of the Oncotype Dx{\circledR} (ODX) on chemotherapy (CTX) utilization in two cancer centers. 276 cases of node-negative ER-positive BC had ODX between 2005 and 2009. Age at diagnosis, tumor size, grade, and progesterone receptor (PR) status were abstracted from records and provided to two medical oncologists blinded to the ODX score. A recommendation for or against CTX was made based on clinicopathologic characteristics. Median age was 55 years. Mean tumor size was 1.6 cm. The median 10-year Adjuvant! Online (AO) mortality risk was 8. The median Nottingham Prognostic Index (NPI) was 3.3. The median ODX recurrence score was 17. Without knowledge of the ODX, oncologists were more likely to recommend CTX to younger women (P < 0.0001), women with negative PR status (P < 0.0001), higher NPI (P < 0.012), and tumors > 1 cm (P = 0.033). On average, CTX recommended patients had larger tumors (2.0 vs. 1.2 cm) and higher AO 10-year mortality (11.4 vs. 4.4{\%}). ODX resulted in a change in management for 38{\%} of women. Of 188 total patients who did not receive CTX, 71 had a recommendation favoring CTX by an oncologist blinded to the ODX score. In our multi-institutional cohort, the ODX score had a significant impact on the receipt of adjuvant CTX and altered management for 38{\%} of women.",
keywords = "Adjuvant chemotherapy, Breast cancer, Oncotype DX",
author = "Ademuyiwa, {Foluso O.} and Austin Miller and Tracey O'Connor and Edge, {Stephen B.} and Thorat, {Mangesh A.} and Sledge, {George W.} and Ellis Levine and Sunil Badve",
year = "2011",
month = "4",
doi = "10.1007/s10549-010-1329-6",
language = "English",
volume = "126",
pages = "797--802",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort

AU - Ademuyiwa, Foluso O.

AU - Miller, Austin

AU - O'Connor, Tracey

AU - Edge, Stephen B.

AU - Thorat, Mangesh A.

AU - Sledge, George W.

AU - Levine, Ellis

AU - Badve, Sunil

PY - 2011/4

Y1 - 2011/4

N2 - The use of clinicopathologic features in decision-making in early stage estrogen receptor (ER)-positive breast cancer (BC) may lead to over or under treatment. We investigated the effect of the Oncotype Dx® (ODX) on chemotherapy (CTX) utilization in two cancer centers. 276 cases of node-negative ER-positive BC had ODX between 2005 and 2009. Age at diagnosis, tumor size, grade, and progesterone receptor (PR) status were abstracted from records and provided to two medical oncologists blinded to the ODX score. A recommendation for or against CTX was made based on clinicopathologic characteristics. Median age was 55 years. Mean tumor size was 1.6 cm. The median 10-year Adjuvant! Online (AO) mortality risk was 8. The median Nottingham Prognostic Index (NPI) was 3.3. The median ODX recurrence score was 17. Without knowledge of the ODX, oncologists were more likely to recommend CTX to younger women (P < 0.0001), women with negative PR status (P < 0.0001), higher NPI (P < 0.012), and tumors > 1 cm (P = 0.033). On average, CTX recommended patients had larger tumors (2.0 vs. 1.2 cm) and higher AO 10-year mortality (11.4 vs. 4.4%). ODX resulted in a change in management for 38% of women. Of 188 total patients who did not receive CTX, 71 had a recommendation favoring CTX by an oncologist blinded to the ODX score. In our multi-institutional cohort, the ODX score had a significant impact on the receipt of adjuvant CTX and altered management for 38% of women.

AB - The use of clinicopathologic features in decision-making in early stage estrogen receptor (ER)-positive breast cancer (BC) may lead to over or under treatment. We investigated the effect of the Oncotype Dx® (ODX) on chemotherapy (CTX) utilization in two cancer centers. 276 cases of node-negative ER-positive BC had ODX between 2005 and 2009. Age at diagnosis, tumor size, grade, and progesterone receptor (PR) status were abstracted from records and provided to two medical oncologists blinded to the ODX score. A recommendation for or against CTX was made based on clinicopathologic characteristics. Median age was 55 years. Mean tumor size was 1.6 cm. The median 10-year Adjuvant! Online (AO) mortality risk was 8. The median Nottingham Prognostic Index (NPI) was 3.3. The median ODX recurrence score was 17. Without knowledge of the ODX, oncologists were more likely to recommend CTX to younger women (P < 0.0001), women with negative PR status (P < 0.0001), higher NPI (P < 0.012), and tumors > 1 cm (P = 0.033). On average, CTX recommended patients had larger tumors (2.0 vs. 1.2 cm) and higher AO 10-year mortality (11.4 vs. 4.4%). ODX resulted in a change in management for 38% of women. Of 188 total patients who did not receive CTX, 71 had a recommendation favoring CTX by an oncologist blinded to the ODX score. In our multi-institutional cohort, the ODX score had a significant impact on the receipt of adjuvant CTX and altered management for 38% of women.

KW - Adjuvant chemotherapy

KW - Breast cancer

KW - Oncotype DX

UR - http://www.scopus.com/inward/record.url?scp=79958755732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958755732&partnerID=8YFLogxK

U2 - 10.1007/s10549-010-1329-6

DO - 10.1007/s10549-010-1329-6

M3 - Article

C2 - 21197567

AN - SCOPUS:79958755732

VL - 126

SP - 797

EP - 802

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -